Literature DB >> 31525619

Predictive value of high titer of GAD65 antibodies in a case of limbic encephalitis.

Roberta Di Giacomo1, Francesco Deleo2, Chiara Pastori3, Giuseppe Didato4, Francesca Andreetta5, Angelo Del Sole6, Marco de Curtis7, Flavio Villani8.   

Abstract

We report the case of a 42-year-old woman who presented with vertigo and migraine and rapidly developed cognitive decline and seizures. Both serum and cerebro-spinal fluid samples showed high titer of anti-glutamic acid decarboxylase (anti-GAD65) antibodies (998,881 IU/ml and 54,687 IU/ml respectively). Limbic encephalitis was diagnosed and high dose steroids treatment started. During one-year follow-up, without further immunomodulatory therapy, the patient became seizure free, and cognitive functions returned to normal. Serum anti-GAD65 antibodies titer decreased significantly but remained elevated (192,680 IU/ml). We discuss the prognostic and pathogenic value of high titer anti-GAD65 antibodies and its variations in a case of autoimmune limbic encephalitis.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anti-glutamic acid decarboxylase 65 antibody; Autoimmune encephalitis; Immunotherapy; Limbic encephalitis; Neuroimmunology

Year:  2019        PMID： 31525619     DOI： 10.1016/j.jneuroim.2019.577063

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  6 in total

Review 1.  GAD antibodies in neurological disorders - insights and challenges.

Authors:  Francesc Graus; Albert Saiz; Josep Dalmau
Journal:  Nat Rev Neurol       Date:  2020-05-26       Impact factor: 42.937

Review 2.  Neurological Syndromes Associated with Anti-GAD Antibodies.

Authors:  Maëlle Dade; Giulia Berzero; Cristina Izquierdo; Marine Giry; Marion Benazra; Jean-Yves Delattre; Dimitri Psimaras; Agusti Alentorn
Journal:  Int J Mol Sci       Date:  2020-05-24       Impact factor: 5.923

3.  Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis: Real-world Evidence From the GENERATE Registry.

Authors:  Franziska S Thaler; Luise Zimmermann; Stefan Kammermeier; Christine Strippel; Marius Ringelstein; Andrea Kraft; Kurt-Wolfram Sühs; Jonathan Wickel; Christian Geis; Robert Markewitz; Christian Urbanek; Claudia Sommer; Kathrin Doppler; Loana Penner; Jan Lewerenz; Rosa Rößling; Carsten Finke; Harald Prüss; Nico Melzer; Klaus-Peter Wandinger; Frank Leypoldt; Tania Kümpfel
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-10-01

4.  Case Report: Multisystem Autoimmune and Overlapping GAD65-Antibody-Associated Neurological Disorders With Beneficial Effect of Epilepsy Surgery and Rituximab Treatment.

Authors:  Petia Dimova; Krassimir Minkin
Journal:  Front Neurol       Date:  2022-01-20       Impact factor: 4.003

5.  Seizures associated with antibodies against cell surface antigens are acute symptomatic and not indicative of epilepsy: insights from long-term data.

Authors:  Anna Rada; Robert Birnbacher; Claudio Gobbi; Martin Kurthen; Albert Ludolph; Markus Naumann; Ulrike Neirich; Tim J von Oertzen; Gerhard Ransmayr; Matthias Riepe; Mareike Schimmel; Oliver Schwartz; Rainer Surges; Christian G Bien
Journal:  J Neurol       Date:  2020-10-06       Impact factor: 4.849

6.  Epilepsy Benchmarks Area III: Improved Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects.

Authors:  Stephen F Traynelis; Dennis Dlugos; David Henshall; Heather C Mefford; Michael A Rogawski; Kevin J Staley; Penny A Dacks; Vicky Whittemore; Annapurna Poduri
Journal:  Epilepsy Curr       Date:  2020-01-22       Impact factor: 7.500
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.